Publications by authors named "C Vidal"

951 Publications

Appropriate Use Criteria (AUC) for Ancillary Diagnostic Testing in Dermatopathology: New Recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology AUC Committee.

J Cutan Pathol 2021 Sep 18. Epub 2021 Sep 18.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Appropriate use criteria (AUC) provide patient-centered physician guidance in test selection. An initial set of AUC were reported by the American Society of Dermatopathology (ASDP) in 2018. AUC reflect evidence collected at single timepoints and may be affected by evolving evidence and experience.

Objective: Update and expand AUC for selected tests.

Methods: RAND/UCLA methodology used includes: 1) Literature review; 2) Review of previously-rated tests and previously-employed clinical scenarios; 3) Selection of previously-rated tests for new ratings; 4) Development of new clinical scenarios; 5) Selection of additional tests; 6) Three rating rounds with feedback and group discussion after rounds 1 and 2.

Results: For 220 clinical scenarios comprising lymphoproliferative (light chain clonality), melanocytic (CGH, FISH, RT-PCR, TERT promoter), vascular disorders (MYC), and inflammatory dermatoses (PAS, GMS) consensus by panel raters was reached in 172/220 (78%) scenarios, with 103/148 (70%) rated "usually appropriate" or "rarely appropriate" and 45/148 (30%), "appropriateness uncertain."

Limitations: The study design only measures appropriateness. Cost, availability, test comparison, and additional clinical considerations are not measured. The possibility that the findings of this study may be influenced by the inherent biases of the dermatopathologists involved in the study cannot be excluded.

Conclusions: AUC are reported for selected diagnostic tests in clinical scenarios that occur in dermatopathology practice. Adhering to AUC may reduce inappropriate test utilization and improve health care delivery. This article is protected by copyright. All rights reserved.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
September 2021

Analysis of serum and endometrial progesterone in determining endometrial receptivity.

Hum Reprod 2021 Aug 12. Epub 2021 Aug 12.

IVI Foundation, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

Study Question: Is there a relationship between serum and endometrial progesterone (P4) levels, including P4 and metabolites (oestrone, oestradiol and 17α-hydroxyprogesterone), and endometrial receptivity?

Summary Answer: Serum P4 levels were not correlated with endometrial P4, nor associated with endometrial receptivity as determined by the ERA® test; however, endometrial P4 and 17α-hydroxyprogesterone levels were positively correlated and related to endometrial receptivity by ERA.

What Is Known Already: Acquisition of endometrial receptivity is governed by P4, which induces secretory transformation. A close relationship between serum P4 and pregnancy outcome is reported for hormone replacement therapy (HRT) cycles. However, the relationship between serum and uterine P4 levels has not been described, and it is unknown whether uterine receptivity depends more on serum or uterine P4 levels.

Study Design, Size, Duration: A prospective cohort study was performed during March 2018-2019 in 85 IVF patients undergoing an evaluation-only HRT cycle with oestradiol valerate (6 mg/day) and micronised vaginal progesterone (400 mg/12 h).

Participants/materials, Setting, Methods: Patients were under 50 years of age, had undergone at least one failed IVF cycle, had no uterine pathology, and had adequate endometrial thickness (> 6.5 mm). The study was conducted at IVI Valencia and IVI Foundation. An endometrial biopsy and a blood sample were collected after 5 days of P4 vaginal treatment. Measures included serum P4 levels, ERA®-based evaluation of endometrial receptivity, and endometrial P4 levels along with metabolites (oestrone, oestradiol and 17α-hydroxyprogesterone) measured by ultra-performance liquid chromatography-tandem mass spectrometry.

Main Results And The Role Of Chance: Seventy-nine women were included (mean age: 39.9 ± 4.6, BMI: 24.2 ± 3.9 kg/m2, endometrial thickness: 8.2 ± 1.4 mm). The percentage of endometria indicated as receptive by ERA® was 40.5%. When comparing receptive versus non-receptive groups, no differences were observed in baseline characteristics nor in steroid hormones levels in serum or endometrium. No association between serum P4 and endometrial steroid levels or ERA result was found (P < 0.05). When the population was stratified according to metabolite concentration levels, endometrial P4 and 17α-hydroxyprogesterone were significantly associated with endometrial receptivity (P < 0.05). A higher proportion of receptive endometria by ERA was observed when endometrial P4 levels were higher than 40.07 µg/ml (relative maximum) and a lower proportion of receptive endometria was associated with endometrial 17α-hydroxyprogesterone lower than 0.35 ng/ml (first quartile). A positive correlation R2 = 0.67, P < 0.001 was observed between endometrial P4 and 17α-hydroxyprogesterone levels.

Limitations, Reasons For Caution: This study did not analyse pregnancy outcomes. Further, the findings can only be extrapolated to HRT cycles with micronised vaginal progesterone for luteal phase support.

Wider Implications Of The Findings: Our findings suggest that the combined benefits of different routes of progesterone administration for luteal phase support could be leveraged to ensure an adequate concentration of progesterone both in the uterus and in the bloodstream. Further studies will confirm whether this method can optimise both endometrial receptivity and live birth rate. Additionally, targeted treatment to increase P4 endometrial levels may normalise the timing of the window of implantation without needing to modify the progesterone administration day.

Study Funding/competing Interest(s): This research was supported by the IVI-RMA Valencia (1706-VLC-051-EL) and Consellería d'Educació, Investigació, Cultura, i esport Generalitat Valenciana (Valencian Government, Spain, GV/2018//151). Almudena Devesa-Peiro (FPU/15/01398) and Cristina Rodriguez-Varela (FPU18/01657) were supported by the FPU program fellowship from the Ministry of Science, Innovation and Universities (Spanish Government). P.D.-G. is co-inventor on the ERA patent, with non-economic benefits. The other authors have no competing interests.

Trial Registration Number: NCT03456375.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
August 2021

Beach morphodynamics and its relationship with the deposition of plastic particles: A preliminary study in southeastern Brazil.

Mar Pollut Bull 2021 Aug 5;172:112809. Epub 2021 Aug 5.

Federal University of São Carlos (UFSCar), Sorocaba Campus, Biology Department, Brazil; Post-graduation Program of Biotechnology and Environmental Monitoring - PPGBMA, Brazil.

This study describes the beach profile, characterizes microplastics and correlates their abundance with morphodynamics characteristics on three beaches from the state of São Paulo, Brazil. 745 particles were found in 4 m of sediment, mostly styrofoam. Nearly 90% of the fragments were found in Boracéia, the most dissipative beach, while less than 1% were found in Juréia beach, the most reflective one. The chemical composition of microplastics was identified by near-infrared hyperspectral imaging (HSI-NIR). The correlation between the abundance of particles and the slope plus the extension of the sand strip was high, as well as that found with the waves' height. These preliminary results indicate that there might be an intrinsic relation among the morphodynamical forces, the movement and destination of microplastics in marine environments.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
August 2021

Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis.

Lung Cancer 2021 09 21;159:153-161. Epub 2021 Jul 21.

Tobacco Control Unit, Cancer Prevention and Control Programme, Institut Català d'Oncologia (ICO)-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat 08908, Barcelona, Spain.

Objectives: Robust economic evaluations are needed to identify efficient strategies for lung cancer prevention that combine brief and intensive smoking cessation intervention programmes with screening using low-dose computed tomography (LDCT) at different ages, frequencies, and coverages. We aimed to assess the cost-effectiveness of smoking cessation approaches combined with lung cancer screening in the European context at a population level from a societal perspective.

Materials And Methods: A microsimulation model that describes the natural history of lung cancer and incorporates several prevention strategies was developed. Discounted lifetime QALYs and costs at a rate of 3% were used to calculate incremental cost-effectiveness ratios, defined as additional costs in 2017 Euros per QALY gained.

Results: Smoking cessation interventions reduce the incidence of lung cancer by 8%-46% and are consistently more effective and cost-effective when starting at younger ages. Screening reduces lung cancer mortality by 1%-24% and is generally less effective and more costly than smoking cessation interventions. The most cost-effective strategy would be to implement intensive smoking cessation interventions at ages 35, 40 and 45, combined with screening every three years between the ages of 55 and 65.

Conclusions: Combining smoking cessation interventions with LDCT screening is a very attractive prevention strategy that substantially diminishes the burden of lung cancer. These combined prevention strategies, especially when providing several intensive interventions for smoking cessation at early ages, are more cost-effective than both approaches separately and allow for a more intensified LDCT without losing efficiency.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
September 2021

Social Cognition and Interaction Training (SCIT) versus Training in Affect Recognition (TAR) in patients with schizophrenia: A randomized controlled trial.

J Psychiatr Res 2021 Oct 23;142:101-109. Epub 2021 Jul 23.

Department of Psychology and Neuroscience, University of North Carolina - Chapel Hill, USA; Australian Catholic University, School of Behavioural and Health Sciences, Melbourne, VIC, Australia.

Introduction: Training in Affect Recognition (TAR) is a "targeted" and computer-aided program that has been shown to effectively attenuate facial affect recognition deficits and improve social functioning in patients with schizophrenia. Social Cognition and Interaction Training (SCIT) is a group "broad-based" intervention, that has also been shown to improve emotion recognition, theory of mind (ToM), and social functioning. To date, no study has compared the efficacy of two different social cognitive interventions.

Objectives: We aim to compare the efficacy of TAR and SCIT on schizophrenia patients' performance on facial affect recognition, theory of mind, attributional style and social functioning before, after treatment, and three months thereafter.

Methods: One hundred outpatients with a diagnosis of schizophrenia were randomly assigned to the TAR or SCIT condition and completed pre- (T0) and posttreatment (T1) assessments and a 3-month follow up (T2) of emotion recognition (ER-40), theory of mind (Hinting Task), attributional style (AIHQ) and social functioning (PSP).

Results: The entire sample, receiving TAR or SCIT, showed improvements in theory of mind, attributional style, clinical symptoms and social functioning. This effect was maintained at three-months. The TAR intervention was more efficacious than the SCIT program in improving the recognition of facial emotions (ER-40). The TAR intervention also demonstrated a lower drop-out rate than the SCIT intervention.

Conclusions: There were improvements in social cognition, symptomatology and functioning of patients in the entire sample, receiving SCIT or TAR. Both TAR and SCIT appear as valuable treatments for people with schizophrenia and social cognitive deficits.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
October 2021